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Aims: Lipopolysaccharide (LPS) induces inflammatory cholestasis by impairing 
expression, localization, and function of carriers involved in bile formation, e.g. bile salt 
export pump (Bsep) and multidrug resistance associated protein 2 (Mrp2). A specific 
therapy against this disease is still lacking. Therefore, we evaluated the anticholestatic 
effects of spironolactone (SL), a PXR ligand that regulates bile salt homeostasis, up-
regulates Mrp2, and bears anti-inflammatory properties. 
Main methods: Male Wistar rats were divided into four groups: Control, SL (83.3 
mg/kg/day of SL, i.p., for 3 days), LPS (2.5 mg/kg/day, i.p., at 8 am of the last 2 days, 
and 1.5 mg/kg/day at 8 pm of the last day), and SL+LPS. Biliary and plasma parameters 
and the expression, function and localization of Mrp2 and Bsep were evaluated. 
Key findings: SL partially prevented LPS-induced drop of basal bile flow by normalizing 
the bile salt-independent fraction of bile flow (BSIBF), via improvement of glutathione 
output. This was due to a recovery in Mrp2 transport function, the major canalicular 
glutathione transporter, estimated by monitoring the output of its exogenously 
administered substrate dibromosulfophthalein. SL counteracted the LPS-induced 
downregulation of Mrp2, but not that of Bsep, at both mRNA and protein levels. LPS 
induced endocytic internalization of both transporters, visualized by 
immunofluorescence followed by confocal microscopy, and SL partially prevented this 
relocalization. SL did not prevent the increase in IL-1β, IL-6, and TNF-α plasma levels. 
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Sepsis-induced cholestasis is a prototypical inflammatory cholestasis [1]. It is caused by 
the impairment in bile production induced by lipopolysaccharide (LPS) of the bacterial 
wall (endotoxins), and the subsequent release of pro-inflammatory cytokines [2]. The 
classic clinical case of sepsis-induced cholestasis is an icteric patient with a Gram (-) 
bacteremia, hospitalized in an intensive care unit. Patients undergoing septic shock may 
develop liver failure [3]. Among the multi-organ failures involved in sepsis, liver 
dysfunction is of remarkable prognostic importance for the clinical course, since it is a 
strong independent predictor of mortality, and therefore, its prevention has become 
imperative [4]. 
Inflammatory cholestasis involves primary alterations in bile formation, generally 
associated with transcriptional and post-transcriptional alterations in the expression 
and/or localization of hepatocellular carriers [5,6]. The canalicular transfer of bile salts 
(BS) by the bile salt export pump (Bsep/Abcb11) and of bilirubin glucuronide/glutathione 
(GSH) by the multidrug resistance-associated protein 2 (Mrp2/Abcc2) is the rate-limiting 
step in the overall transport from plasma to bile for these compounds. The expression of 
Bsep and Mrp2 is decreased in sepsis-induced cholestasis [7]. Transcriptional 
alterations of these carriers are mainly due to the repressed expression of nuclear 
receptors, such as pregnane X receptor (PXR) [8]. Inflammatory cholestasis also 
causes short-term, post-translational deleterious effects on canalicular transporter 













In a previous work [10], we studied the anti-cholestatic effects of ursodeoxycholic acid 
(UDCA) in LPS-induced cholestasis, as it is the “first choice” therapeutic approach for 
most cholestatic hepatopathies. Since its beneficial effects were partial, we decided to 
evaluate spironolactone (SL) as a complementary anti-cholestatic agent, which could 
act via alternative pathways. SL is a medicine used as a diuretic agent to reduce high 
blood pressure and edema, and for the treatment of heart failure [11]. It is also a 
transactivating ligand of the nuclear receptor PXR [12,13], a transcription factor that up 
regulates Mrp2 expression and regulates genes involved in BS homeostasis, which 
could be beneficial in this kind of cholestasis [14]. Modulating effects of SL on bile 
secretion have been described, as a result of increments in Mrp2 expression and the 
consequent higher secretion of GSH, a main driving force of the so called bile salt-
independent fraction of bile flow (BSIBF) [15]. In addition, beneficial effects of SL in a 
model of non-inflammatory cholestasis in rodents induced by ethynylestradiol have 
been described [16]; a similar anticholestatic effect in an inflammatory model of 
cholestasis cannot be however inferred, since both kinds of cholestasis involves a 
differential subset of nuclear receptors [8], and are triggered by dissimilar signaling 
mechanisms [9]. Finally, anti-inflammatory properties of PXR have also been reported 
[17,18], and this could be particularly relevant for inflammatory hepatopathies like the 
one we are studying here. 
Since there have been no studies to date showing that SL is able to counteract some of 
the alterations that occur in inflammatory cholestasis, in this study we evaluated the 













2. Materials and methods 
2.1. Chemicals 
LPS from Salmonella typhimurium, SL, NADPH, and GSH reductase were purchased 
from Sigma-Aldrich (St. Louis, MO). Sodium taurocholate (TC) was purchased from 
Santa Cruz Biotechnology (Dallas, Texas, U.S.A.). Dibromosulfophthalein (DBSP) was 
obtained from the Société d´Etudes et de Recherche Biologique (Paris, France). All 
other chemicals were of analytical grade purity, and used as supplied. 
2.2. Animals and treatments 
Adult male Wistar rats (90 days), weighing 300-350 g, were used. They were obtained 
from the Center for Comparative Medicine, Institute of Veterinary Sciences of Litoral, 
UNL-CONICET. Animals were maintained with a standard diet, water and saline 
solution ad libitum, under a constant 12 h-light/12 h-dark cycle. During the experiments, 
vital signs (heart rate and respiratory rate) and pain sensitivity were monitored. All 
treatments and animal experiments were carried out in the Institute of Experimental 
Physiology (IFISE). Animals received humanitarian care according to, the "Guide for the 
care and use of laboratory animals" published by the National Institutes of Health (NIH 
Publications No. 8023, revised 1978) and the ARRIVE (Animal Research: Reporting In 
Vivo Experiments) guidelines (http://www.nc3rs.org/ARRIVE). Animal experiments were 
approved by the Bioethics Committee for the Care and Use of Laboratory Animals of the 












Rosario (Resolution No. 489/2015). 
Rats were randomized in the following four experimental groups: 
LPS group: Animals were injected with SL vehicle (corn oil i.p. at a daily dose of 5.85 
ml/kg of b.w. and 6% DMSO), for 3 consecutive days. Animals also received 3 LPS 
doses, as follows: at 8:00 am of the last two days, the animals were given a single, i.p. 
injection of LPS of Salmonella typhimurium (2.5 mg/kg/day of b.w., dissolved in saline) 
and, at 8:00 pm of the last day, a third dose of LPS of 1.5 mg/kg of b.w. was injected. 
Due to the high variability of LPS dosage to induce cholestasis in the literature, this 
treatment protocol was established in ancillary experiments where different dosages 
were tested, aimed to obtain consistent drops in bile flow with minimal side effects. 
SL group: Animals were injected with SL, i.p., at a dose of 83.3 mg/kg of b.w., dissolved 
in corn oil and 6% DMSO, for 3 days; at this dosage, we showed that SL induces both 
choleresis to untreated rats [15] and anti-cholestatic effects in rats treated with ethynyl 
estradiol [16]. 
SL + LPS group: Animals were injected with SL and with 3 LPS doses, as indicated in 
the previous groups. 
Control group: Animals were injected only with LPS and SL vehicles. 
Rats were provided with saline solution to drink “ad libitum” to compensate possible 
excess of NaCl loss due to SL diuretic effects. Since, according to set-up, ancillary 












animals drunk approx. 3 ml or 6 ml in average less saline depending on their lethargic 
state (over or subtle), they received additionally one or two daily subcutaneous 
injections of saline solution of 3 ml each. 
2.3. Surgical procedures 
After the treatments were completed, and 12 hs after the last dose of LPS, animals 
were anesthetized with ketamine/xylazine (100 mg/kg of b.w. and 3 mg/kg of b.w., i.p., 
respectively), and thus maintained throughout the experiment. Body temperature was 
monitored with a rectal probe, and maintained between 36 and 37.5 °C with a heating 
lamp. Then, the common bile duct and the femoral vein were cannulated with PE10 and 
PE50 polyethylene tubing, respectively (Intramedic, Clay Adams, Parsippany, NJ) to 
collect bile samples and carry out transporter functionality estimations. At the end of the 
experiments, the animals were euthanized by exsanguination, and blood and liver 
samples were collected for further studies. 
2.4. Bile and plasma samples collection and analytical procedures 
Bile samples were collected for 10 min to monitor basal bile flow (BF), which was 
determined gravimetrically assuming a density of 1 g/ml. Basal bile was assayed for 
both total bile acids (TBA) and GSH, the two main biliary solutes acting as driving force 
for bile formation [19]. TBA in bile were measured by using the commercial kit RANDOX 
Laboratories Limited (Crumlin, United Kindom) (TBA, 5th generation, enzymatic 












method of Tietze [20], as modified by Griffith [21]. Once finished the bile collection 
period, animals were euthanized by exsanguination, and the liver removed. In order to 
evaluate the degree of the hepatic injury, plasma samples were assayed for alkaline 
phosphatase (ALP; EC 3.1.3.1), aspartate aminotransferase (AST; EC 2.6.1.1), alanine 
aminotransferase (ALT; EC 2.6.1.2), and lactate dehydrogenase (LDH; EC. 1.1.1.27) by 
using a CM250 Autoanalyzer (Wiener Lab, Rosario, Argentina). 
A blood sample from the tail vein was also obtained 2 h after the second LPS injection, 
to measure plasma levels of the inflammatory cytokines IL 1-β, IL-6 and TNF-α, by 
using commercial kits (IL-1 beta Rat ELISA Kit, IL-6 Rat ELISA Kit, TNF alpha Rat 
ELISA Kit from Invitrogen, Waltham, Massachusetts, USA). 
2.5. Biliary excretion of exogenous Mrp2 and Bsep substrates 
The time-course of the changes in the biliary output of the exogenously administered 
Bsep and Mrp2 solutes TC [10] and DBSP [22], respectively, have been assessed to 
estimate in vivo the transport efficiency of these canalicular carriers. Despite uptake of 
these solutes may be affected by LPS treatment [23], this process is unlikely to 
significantly influence biliary excretion, because 1) canalicular transfer but not 
basolateral uptake is the rate-limiting step in the hepatic handling of cholephilic 
compounds [24], and 2) kinetic studies suggest that the ABC canalicular transporters 
work under Tm conditions [25], so that changes in intracellular levels due to impaired 












to be modified by LPS, because canalicular excretion is impaired to a similar or even 
higher extent than uptake by endotoxin [26]. 
TC, a model BS that is excreted into the canalicular lumen by Bsep [27], was injected at 
a single, i.v. dose of 8 μmol/100 g b.w. [10]. Then, bile samples were collected every 2 
min for 10 min. According to ancillary experiments, after this time period, the 
exogenously administered TC has been completely cleared in control animals (data not 
shown). Therefore, TBA were measured in bile, and TC excretion was calculated by 
assuming that all the excess in biliary excretion rate of TBA over the basal one after TC 
injection is fully due to TC excretion, as shown elsewhere [10]. 
Mrp2 functionality was estimated by using DBSP, since this dye excreted into the 
canalicular lumen by this transporter after having been taken up by the hepatocyte by 
the organic anion-transporting polypeptide [22]; DBSP is not conjugated within the 
hepatocyte [28], and therefore its biliary excretion is independent on the changes in 
conjugation enzyme levels induced by SL [29]. To carry out the study, DBSP was 
administered at a single, i.v. dose of 15 mg/kg of b.w. Bile samples were then collected 
in 5-min intervals over the next 60 min, a time period long enough to virtually fully 
depurate the dye in control animals (data not shown). DBSP in bile was determined by 













2.6. Assessment of BSIBF 
Since BS are osmotic entities capable of stimulating bile formation, there is a direct and 
linear relationship between BF and TBA output [31], as follows: 
BF = m.TBA output + h 
Where: 
m = Choleretic efficiency of BS. 
h = BSIBF 
To obtain the parameters of this equation, a bolus of TC was administered i.v. at the 
dose of 8 μmol/100 g of b.w., and bile was collected every 2 min for 10 min. TBA were 
measured in bile and the TBA output was calculated as previously indicated above. BF 
vs. TBA output values were plotted, and a linear regression curve was fitted for each set 
of values, with y-intercept and slope being BSIBF and choleretic efficiency, respectively. 
2.7. Bsep and Mrp2 protein expression 
Western blot analyses of Bsep and Mrp2 in total homogenate and fractions enriched in 
canalicular membrane proteins were performed as described previously [32]. Then, 
samples were loaded on polyacrylamide gels under denaturing conditions, and then 
subjected to electrophoresis. Once the electrophoresis was completed, proteins were 
transferred from the gel to PVDF membranes. Subsequently, the membranes were 
removed and blocked with buffer (50 ml PBS 1X, Tween 0.3% and 5 g of low fat dry 
milk) for at least 1 h. After blocking, they were incubated with the primary antibodies 












Biochemicals, Carlsbad, CA; or polyclonal rabbit anti-rat Bsep antibody, 1:1000, Anti-
SPGP pAb, Kamiya Biomedical Company, Seattle, WA USA). The next day, the 
membranes were washed, and immune complexes were detected by incubation with 
horseradish peroxidase linked to secondary antibodies for 1 h. Immunoreactive bands 
were detected using a bioluminescent reagent (ECL, Amersham Pharmacia Biotech, 
Inc). Membranes were re-probed with an anti-β actin antibody as loading control 
(Sigma–Aldrich Corp). Subsequently, the bands were quantified by densitometry, using 
the Gel Pro Analyzer Software (Media Cybernetics, Silver Spring, MD).  
2.8. Real-time PCR study of Bsep and Mrp2 
Total RNA was isolated from liver tissue using TRIzol® reagent (Invitrogen), according 
to manufacturer's instructions. Yield, purity, and integrity of RNA were assessed. Then, 
the first strand cDNA was synthesized using Superscript III Reverse Transcriptase and 
random primers (Invitrogen), according to the manufacturer’s suggested protocol. 
Sequences of primer pairs and conditions for Mrp2, Bsep, and 18S were as previously 
described [10,16] (Table 1). Real-time PCR reactions were carried out in a Mx3000P 
System (Stratagene, La Jolla, CA) with Platinum Taq DNA Polymerase (Invitrogen) and 
SYBR Green quantification, according to the manufacturer's instructions. Results for 
Mrp2 and Bsep mRNA were normalized to the expression of 18S rRNA as the 













Table 1. Sequence of primers used in Real-time PCR. 











2.9. Immunofluorescence detection of Bsep and Mrp2  
Liver pieces were immersed in isopentane at -70 °C, immediately removed, and stored 
at -70 °C until use. The tissues were then cut into 5 μm slices with a cryostat, fixed and 
stained, as described previously [34]. For immunolabeling, tissue sections were 
incubated overnight with a rabbit anti-rat Bsep (1:200; Kamiya Biomedical Co., Seattle, 
WA, USA), or with a mouse anti-rat Mrp2 (1:200; [M2III-6]; Alexis Biochemicals, San 
Diego, CA, USA), followed by incubation with a Cy2-conjugated donkey anti-rabbit IgG 
or a Cy2-conjugated donkey anti-mouse IgG, respectively (1:200, 1 h; Jackson 
ImmunoResearch Laboratory, West Grove, PA). To delimitate the bile canaliculi, the 
tight junctional-associated protein occludin was used. Occludin was labeled with a 












Invitrogen) or with a rabbit anti-rat occludin (when Mrp2 immunostaining was carried 
out, 1:200, overnight; Zymed, San Francisco, USA), followed by incubation with a Cy3-
conjugated donkey anti-mouse or a Cy3-conjugated donkey anti-rabbit (1:200, 1 h, 
Jackson ImmunoResearch Laboratory, West Grove, PA.), respectively. The images 
were captured on a LSM880, Carl Zeiss LLC (Thornwood, NY, USA) confocal 
microscope. To ensure comparable staining and image capture performance for all 
groups, liver slices were prepared on the same day, mounted on the same glass slide, 
and subjected to the staining process and microscopy analysis simultaneously. 
Quantification of the degree of Bsep and Mrp2 endocytic internalization was performed 
on confocal images using ImageJ 1.34 m (National Institutes of Health), as described by 
us elsewhere [35]. For this purpose, fluorescence intensity associated with the 
transporters along an 8 μm line perpendicular to the canaliculus (from −4 μm to 4 μm of 
the canalicular center) was assessed. For each section, data from at least 10 different 
canaliculi were collected, and used for statistical comparison. 
2.10. Statistical analysis 
Data are expressed as means ± SEM. Statistical analysis was carried out by using 
ANOVA or Student t test, unless another statistical test has been determined to be more 
appropriate. The variances of the densitometric profiles of Bsep and Mrp2 localization 
were compared with the Mann-Whitney U test [36]. Values of P < 0.05 were considered 













3.1. Biliary and plasma parameters of cholestasis 
A significant decrease in BF was observed in LPS group while, in the co-treated group, 
BF was restored to control values (Table 2). At the same time, there was a tendency to 
increase BF in SL-treated animals. A decrease in TBA output and in total GSH output 
was observed in the LPS group. In the SL+LPS group, TBA output remained 
unchanged as compared to the LPS group. However, total GSH output was significantly 
increased in the co-treated group, as compared to the LPS group. There was a 
tendency to increase in total GSH output in the SL group compared with control group. 
These changes in GSH excretion were in agreement with the changes observed in 
BSIBF. This parameter accounted for 88% of total basal bile flow, a relative contribution 
in line with previous results from us [15,37] and others [38,39], and was reduced by 
37% in LPS-treated rats. SL had a tendency towards increasing BSIBF when 













Table 2. Basal biliary parameters. 
 
Control SL LPS SL+LPS 
BF (μl/min per g liver) 3.5 ± 0.1 3.9 ± 0.2 2.4 ± 0.1* 3.1 ± 0.2# 
TBA output  
(nmol/min per g liver)  
52 ± 8 43 ± 7 31 ± 3* 30 ± 4* 
Total GSH output 
(nmol/min per g liver) 
1.35 ± 0.11 1.71 ±  0.24 0.37 ± 0.05* 0.76 ± 0.12*# 
BSIBF 
(μl/min per g liver)  
3.0 ± 0.3 3.6 ± 0.2 1.9 ± 0.1* 2.8 ± 0.1# 
BF, bile flow; BSIBF; bile salt independent bile flow; GSH, glutathione; LPS, 
lipopolysaccharide; SL, spironolactone; TBA, total bile acids. 
*P < 0.05 vs. control; #P < 0.05 vs. LPS. n = 3-15. 
 
Regarding plasma biochemical parameters, ALP was increased in the LPS group and 
this was not prevented by the SL pre-treatment (Table 3). On the other hand, there were 
no changes in plasma levels of AST, ALT, and LDH in LPS-treated animals compared 












Table 3. Plasma biochemical parameters. 
 Control SL LPS SL+LPS 
ALP (U/l) 370 ± 24 402 ± 43 535 ± 56* 516 ± 68* 
AST (U/l) 135 ± 16 113 ± 11 145 ± 27 168 ± 23 
ALT (U/l) 42 ± 16 35 ± 7 41 ± 16 28 ± 7 
LDH (U/l) 381 ± 29 364 ± 24 559 ± 119 640 ± 197 
ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; SL, 
spironolactone; TBA, total bile acids. 
*P < 0.05 vs. control; #P < 0.05 vs. LPS. n = 4-13. 
 
3.2. Biliary excretion of exogenous Mrp2 and Bsep substrates 
Mrp2 transport activity was estimated following a bolus injection of DBSP, a model Mrp2 
substrate. As depicted in Fig. 1, DBSP was transported less efficiently by LPS-treated 
rats. This impairment was however partially counteracted by SL pre-treatment, since 
cumulative biliary excretion of DBSP in the co-treated rats was intermediate between 












output of GSH, a Mrp2 substrate, further supporting the fact that SL pre-treatment 
prevented the Mrp2 secretory failure induced by LPS. 
 
Figure 1. Upper panel. Cumulative biliary excretion of dibromosulfophthalein 
(DBSP). Bile samples were collected every 5 min for 60 min, after a single, i.v. dose of 
15 mg/kg of b.w. Lower panel. Area under the curve (AUC) of cumulative biliary 












SEM, for 3-5 individual experiments. Data are shown as mean ± SEM. *P < 0.05 vs. 
control; #P < 0.05 vs. LPS. 
Bsep transport function was estimated by recording changes over time in biliary 
excretion of TC, following a bolus injection of this compound. Then, BF and TBA output 
over basal values, attributed to the output of exogenously administered TC, were 
analyzed (Table 4, Fig. 2). A decrease in these parameters was found in the LPS group. 
In the SL+LPS group, TBA output values remains similar to those in the LPS group. SL 
had per se an inhibitory effects on TC biliary excretion, but the difference was only 
apparent during the first two time periods of bile collection after TC injection. 
Table 4. TC-stimulated biliary parameters. 
 
Control SL LPS SL+LPS 
TC-stimulated† BF  
(μl/min per g liver) 5.8 ± 0.1 5.5 ± 0.1 3.4 ± 0.1* 4.3 ± 0.1*# 
TC-stimulated† TBA output 
(nmol/min per g liver) 237 ± 17 212 ± 37 129 ± 9* 151 ± 3* 
BF, bile flow; LPS, lipopolysaccharide; SL, spironolactone; TC, taurocholate; TBA, total 
bile acids. 
†TC-stimulated values correspond to the maximum value obtained after a TC i.v. 
injection of 8 μmol/100 g of b.w. 













Figure 2. Upper panel. Cumulative biliary excretion of taurocholate (TC). Bile 
samples were collected every 2 min for 10 min, after a single, i.v. dose of 8 μmol/100 g 
of b.w. of the BS. Lower panel. Area under the curve (AUC) of cumulative biliary 
excretion of TC. LPS, lipopolysaccharide; SL, spironolactone. Data are mean ± SEM, 
for 3 individual experiments. Data are shown as mean ± SEM. *P < 0.05 vs. control; #P 













3.3. Mrp2 and Bsep mRNA expression 
In LPS-treated animals, a decrease in both Mrp2 and Bsep, was observed. In SL+LPS 
co-treated animals, an increase in Mrp2, but not in Bsep mRNA expression was found 
(Table 5). An increase in Mrp2 mRNA expression in SL group was also recorded. 
Table 5. Mrp2 and Bsep mRNA expression by Real-time PCR. 
LPS, lipopolysaccharide; SL, spironolactone. 
*P < 0.05 vs. control; #P < 0.05 vs. LPS. n = 3-7. 
 
3.4. Western blot analysis of Mrp2 and Bsep expression 
Mrp2 protein expression was significantly reduced, both at plasma membrane and total 
homogenate levels, in the LPS-treated group (Fig. 3). An increase in SL+LPS co-treated 
animals was observed in both fractions. In SL control group, Mrp2 protein expression 
increase in total homogenate and plasma membrane. This is in agreement with the 
mRNA levels 
(% of mean control values) 
Control SL LPS SL+LPS 
Mrp2 100 ± 6 145 ± 2* 64 ± 5* 85 ± 6# 


























Figure 3. Protein expression of Mrp2. A. Western blot analysis of Mrp2 in liver 
homogenate. B. Western blot analysis of Mrp2 in liver plasma membranes. Data 
on densitometric analysis are presented as percentages and were referred to control, 
considered as 100%. Differences in sample loading were corrected by the densitometric 
signal of the corresponding actin band. LPS, lipopolysaccharide; SL, spironolactone. 
Data are shown as mean ± SEM. *P < 0.05 vs. control; #P < 0.05 vs. LPS. n = 8-10. 
A decrease in Bsep protein expression was also found in liver plasma membranes and 
homogenate in the LPS-treated group (Fig. 4). In SL+LPS co-treated animals, an 
increase in Bsep protein expression at the plasma membrane level was observed, but 
not in liver homogenate. Although, there was a tendency towards increased Bsep 
protein levels in homogenate when compared to the LPS group, the difference did not 













Figure 4. Protein expression of Bsep. A. Western blot analysis of Bsep in liver 












on densitometric analysis are presented as percentages and were referred to control 
considered as 100%. Differences in sample loading were corrected by the densitometric 
signal of the corresponding actin band. LPS, lipopolysaccharide; SL, spironolactone. 
Data are shown as mean ± SEM. *P < 0.05 vs. control; #P < 0.05 vs. LPS. n = 6-10. 
 
Due to the increase in the protein expression levels of both transporters in liver 
membranes, a possible post-translational regulation associated with an improvement in 
plasma membrane localization was suggested. Therefore, we studied their localization 
status by confocal microscopy. 
 
3.5. Mrp2 and Bsep localization by immunofluorescence followed by 
confocal microscopy 
Fig. 5A shows confocal images of Mrp2 (stained in green) and occludin, used as a 
marker of the bile canaliculus edge (stained in red). The transporter was localized in the 
canalicular membrane in liver slices of control and SL-treated animals, while in livers of 
the LPS group, a re-localization of Mrp2 outside the limits of the canaliculus was 
observed. Pretreatment with SL prevented this internalization of Mrp2 from the 
canalicular membrane to pericanalicular endosomes. Fig. 5B shows the distribution 
profiles of transporter-associated fluorescence along a line perpendicular to the bile 
canaliculus. Analysis of the distribution profiles of occludin demonstrates a conserved 












that could have affected localization of Bsep. The same results were observed for Bsep 
localization analysis (Fig. 6). 
 
Figure 5. Endocytic internalization of Mrp2. A. Representative confocal images 
showing co-immunostaining of Mrp2 (green) and occludin (red; marker of the bile 
canaliculus edge), illustrative of the endocytic internalization of Mrp2 induced by 
lipopolysaccharide (LPS; arrows), and its prevention by spironolactone (SL). B. Lower 
panels show densitometric analysis of the fluorescence intensity associated with Mrp2 
or occluding, along an 8-μm line perpendicular to the bile canaliculus (from −4 μm to +4 
μm from the canalicular centre), corresponding to the confocal images shown in the 













Figure 6. Endocytic internalization of Bsep. A. Representative confocal images 
showing co-immunostaining of Bsep (green) and occludin (red; marker of the bile 
canaliculus edge), illustrative of the endocytic internalization of Bsep induced by 
lipopolysaccharide (LPS; arrows), and its partial prevention by spironolactone (SL). B. 
Lower panels show densitometric analysis of the fluorescence intensity associated with 
Bsep or occludin along an 8-μm line perpendicular to the bile canaliculus (from −4 μm to 
+4 μm from the canalicular centre), corresponding to the confocal images shown in the 













3.6. Pro-inflammatory cytokines 
IL-1β, TNF-α and IL-6 were increase in LPS-treated animals, 2 hours after the second 
dose of LPS. However, SL pre-treatment did not prevent these effects (Table 6). We 
therefore inferred that the beneficial effects of SL did not involve inhibition of the 
inflammatory response. 
Table 6. Plasma levels of pro-inflammatory cytokines, IL-1β, TNF-α and IL-6. 
Pro-inflammatory cytokines Control SL LPS SL+LPS 
IL-1β (pg/mL) 190 ± 44 198 ± 45 648 ± 78* 517 ± 61* 
TNF-α (pg/mL) 13 ± 1 8 ± 1 30 ± 9 17 ± 1* 
IL6 (pg/mL) 108 ± 24 129 ± 35 2130 ± 222* 1685 ± 101* 
IL-1β, interleukin-1β; IL-6, interleukin-6; LPS, lipopolysaccharide; SL, spironolactone 
TNF-α, tumor necrosis factor-α. 












In this study, we showed that SL was instrumental in preventing some relevant 
cholestatic effects of LPS. It extensively improved the BSIBF, a phenomenon involving 
restoration of the biliary excretion of GSH, the main solute responsible for its generation 
[40], via a functional improvement of its canalicular transporter Mrp2, through both 
transcriptional and post-transcriptional mechanisms. 
In a previous work [10], we analyzed the anti-cholestatic effects of UDCA, the first-
choice therapy for most cholestatic diseases, in LPS-induced cholestasis. We found that 
UDCA has only partial effects on the restoration of the biliary secretory function, which 
are complementary to the anti-cholestatic mechanisms shown to be afforded here by 
SL. Indeed, UDCA was unable to improve BSIBF, as a consequence of its inability to 
prevent the functional failure and protein expression impairment of Mrp2 induced by 
LPS. Therefore, in an attempt to restore Mrp2 functionality, we assayed an alternative 
anti-cholestatic strategy based on the transactivation of PXR, the main nuclear receptor 
responsible for regulating Mrp2 expression [41], by using SL, a recognized PXR ligand 
able to improve Mrp2 expression at a transcriptional level [15]. 
Although, in humans, one of the most potent PXR ligands is rifampicin [42], it is a weak 
ligand in rodents, so that we decided to use SL, as an alternative ligand with far higher 
affinity for rat PXR [12,13]. 
BF restoration was observed towards control levels in co-treated animals (see Table 2). 












total GSH output in co-treated animals compared to LPS group (see Table 2). GSH is 
excreted towards the lumen of the bile canaliculus via Mpr2 [43], so that an increase in 
its excretion could indicate an improvement in transporter functionality. To become 
independent of possible variations in intracellular GSH levels, we studied Mrp2 
functionality by using the exogenous substrate of the transporter, DBSP. We recorded 
an improvement in DBSP excretion in co-treated animals (see Fig. 1), thus confirming 
an increase in Mrp2 functionality in SL+LPS co-treated animals. When evaluating Mrp2 
mRNA levels, we observed an increase in co-treated animals compared to the LPS 
group (see Table 5), which was correlated with increased protein levels, both in plasma 
membrane fraction and in total homogenate (see Fig. 3). This is most likely related to 
the transactivating effect of SL on PXR, since, PXR positively modulates Mrp2 
expression [14,15]. Regardless of the mechanisms involved, the complete restoration of 
Mrp2 activity in LPS-treated rats could have important clinical implications, not only by 
ameliorating the cholestasis itself but also by counteracting the hyperbilirubinemia that 
occurs in sepsis-induced cholestasis [1]. Indeed, Mrp2 is the limiting step for bilirubin 
metabolite excretion into bile [44], and its improvement should certainly result in an 
improved biliary clearance of this potentially toxic compound. Unfortunately, the rat has 
a very high reserve capacity to clear bilirubin, with t1/2 being 26 times faster than in 
humans [45], and therefore its levels were not increased in plasma in our model (data 
not shown), thus preventing us from ascertaining whether SL is actually effective in 
reducing bilirubin levels in an hyperbilirubinemic condition associated with endotoxemia. 
Regarding Bsep, mRNA levels in the SL+LPS co-treated group remained lower than 












reflected in low Bsep protein expression levels in total homogenate in the co-treated 
group (see Fig. 4), and low biliary excretion of BS, both under basal and TC-stimulated 
conditions (see Tables 2 and 4, and Fig. 2). This finding is consistent with the high ALP 
plasma levels observed in the co-treated animals (see Table 3). We inferred that 
hepatocytes would not be able to counteract BS overload through the Bsep canalicular 
transporter, and this would generate a removal of protein components from the plasma 
membrane due to its surfactant effect, thus releasing ALP to plasma. These results are 
consistent with previous studies where there were no changes in Bsep expression in 
rats treated with SL alone [15], or in the expression of the BS export pump Mrp3 
involved in basolateral BS efflux either in normal rats or in rats with ethynylestradiol-
induced cholestasis [16]. 
An increase in Bsep protein levels was found in the plasma membrane fraction 
(although not in total homogenate) (see Fig. 4), which would indicate some kind of post-
translational regulation, for example, increased transporter stability in the canalicular 
membrane against the endocytic stimulation induced by LPS [9]. This beneficial effect of 
SL was also extended to Mrp2, since it was also better localized in plasma membrane in 
the co-treated group. To test this hypothesis, we studied the subcellular localization of 
Mrp2 and Bsep by confocal microscopy, and we confirmed that both Mrp2 and Bsep are 
better located in the canaliculi in co-treated animals, but not in the LPS group, where 
the transporter is internalized in intracellular vesicular compartments (see Figs. 5 and 
6); this contributes to explain the recovery in the expression of both transporters in the 
plasma membrane fraction. This post-translational effect of SL was somewhat 












mechanisms. However, some properties of SL on liver structure and function provide 
some hints. SL decreases plasma membrane fluidity, as a result of an increase in 
cholesterol and a decrease in phospholipids [46]. On the other hand, LPS treatment 
decreases cholesterol content in the canalicular membrane [47], an effect that could 
have been counteracted by SL co-treatment. SL effect would enable the stabilization of 
the transporters in lipid raft microdomains, thus preventing their transfer to non-raft 
structures, and their further endocytosis via a clathrin-dependent mechanism [48]. 
Another possibility could involve certain antioxidant effects exerted by SL. 
Internalization of transporters in LPS-induced cholestasis, but not the transporter 
downregulation at transcriptional level, has been causally associated with the induction 
of oxidative stress caused by endotoxin, since antioxidant agents completely prevented 
this effect [49]. Suggestively, SL showed antioxidant effects in a wide variety of tissues 
and, particularly, in the liver, where it was able to inhibit pro-oxidant systems (e.g., 
NADPH oxidase) [50] and induce antioxidant systems (e.g., catalase) [51]. 
Undoubtedly, this and other effects of SL not related to PXR deserve to be studied in 
more detail to fully understand its post-transcriptional anti-cholestatic action 
mechanisms. 
The improvement in Bsep localization in plasma membrane in SL+LPS co-treated 
animals compared to LPS-treated group did not have the expected impact on its 
transporter activity (see Table 4 and Fig. 2). This result would indicate that, although 
Bsep is correctly localized, its intrinsic transport activity is selectively inhibited. Although 
an increase in membrane cholesterol could be beneficial because it improves its 












canalicular membrane fluidity [52], a factor thought to influence Bsep transport activity 
[53,54]; this may explain the somewhat lower Bsep-mediated transport of the 
exogenously administered TC in the SL alone group (see Fig. 2). The 'rigidizing' effect 
of SL could be particularly detrimental in endotoxemic rats, since LPS per se reduces 
hepatocellular membrane fluidity by increasing the cellular influx of Ca2+ [55], an effect 
that would add to the 'rigidizing' effect of SL itself, which may further decrease plasma 
membrane fluidity by alternative mechanisms associated with its effect as an 
aldosterone antagonist or as an estrogen-mimetic compound [46]. Unlike Bsep, 
circumstantial evidence suggest that Mrp2 transport function is scantily influenced by 
diminutions of plasma membrane fluidity [54], thus explaining the lack of impairment in 
DBSP biliary excretion when SL was administered alone (see Fig. 1), and the good 
relationship between improved localization and enhanced function observed for Mrp2 in 
SL+LPS co-treated group (see Figs. 1 and 5), as opposed to Bsep. 
Finally, we evaluated the potential anti-inflammatory role of SL as PXR ligand in LPS-
induced cholestasis, because this effect of PXR had been shown in other inflammatory 
models [17,18]. For this purpose, we determine a series of pro-inflammatory cytokines 
in plasma (see Table 6). We do not observe changes in their plasma levels in the 
SL+LPS group compared to the LPS group, thus ruling out the possibility that the SL 
acts in this model via inhibition of NF-κB [18], the main transcription factor mediating 
LPS-induced inflammatory response. Although, anti-inflammatory effects of SL had 
been previously described, they are not related to its properties as PXR activator, but to 
the antagonistic effect on aldosterone, an ubiquitous hormone that exerts pro-













Our results show that the PXR ligand SL contributes to normalize BF in LPS-induced 
cholestasis by improving Mrp2 expression and localization, thus allowing the recovery of 
mechanisms of bile formation independent of BS excretion. This properly complements 
others experimental anti-cholestatic approaches that, like that involving UDCA 
administration, failed to improve these mechanisms of BF generation while improving 
others related to BS excretion. This allows to envisage the need for complementary co-
treatments to successfully treat this complex condition, with PXR ligands been key parts 
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Table 1. Sequence of primers used in Real-time PCR. 























Table 2. Basal biliary parameters. 
 
Control SL LPS SL+LPS 
BF (μl/min per g liver) 3.5 ± 0.1 3.9 ± 0.2 2.4 ± 0.1* 3.1 ± 0.2# 
TBA output  
(nmol/min per g liver)  
52 ± 8 43 ± 7 31 ± 3* 30 ± 4* 
Total GSH output 
(nmol/min per g liver) 
1.35 ± 0.11 1.71 ±  0.24 0.37 ± 0.05* 0.76 ± 0.12*# 
BSIBF 
(μl/min per g liver)  
3.0 ± 0.3 3.6 ± 0.2 1.9 ± 0.1* 2.8 ± 0.1# 
     
BF, bile flow; BSIBF; bile salt independent bile flow; GSH, glutathione; LPS, 
lipopolysaccharide; SL, spironolactone; TBA, total bile acids. 













Table 3. Serum biochemical parameters. 
 Control SL LPS SL+LPS 
ALP (U/l) 370 ± 24 402 ± 43 535 ± 56* 516 ± 68* 
AST (U/l) 135 ± 16 113 ± 11 145 ± 27 168 ± 23 
ALT (U/l) 42 ± 16 35 ± 7 41 ± 16 28 ± 7 
LDH (U/l) 381 ± 29 364 ± 24 559 ± 119 640 ± 197 
ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; 
LDH, lactate dehydrogenase; LPS, lipopolysaccharide; SL, spironolactone; TBA, total bile 
acids. 













Table 4. TC-stimulated biliary parameters. 
 
Control SL LPS SL+LPS 
TC-stimulated† BF (μl/min per g 
liver) 
5.8 ± 0.1 5.5 ± 0.1 3.4 ± 0.1* 4.3 ± 0.1*# 
TC-stimulated† TBA output 
(nmol/min per g liver) 
237 ± 17 212 ± 37 129 ± 9* 151 ± 3* 
BF, bile flow; LPS, lipopolysaccharide; SL, spironolactone; TC, taurocholate; TBA, total bile 
acids. 
†TC-stimulated values correspond to the maximum value obtained after a TC i.v. injection of 
8 μmol/100 g of b.w. 













Table 5. Mrp2 and Bsep mRNA expression by Real-time PCR. 
LPS, lipopolysaccharide; SL, spironolactone. 
*P < 0.05 vs. control; #P < 0.05 vs. LPS. n = 3-7. 
  
mRNA levels 
(% of mean control values) 
Control SL LPS SL+LPS 
Mrp2 100 ± 6 145 ± 2* 64 ± 5* 85 ± 6# 












Table 6. Plasma levels of pro-inflammatory cytokines IL-1β, TNF-α, and IL-6. 
Pro-inflammatory cytokines Control SL LPS SL+LPS 
IL-1β (pg/mL) 190 ± 44 198 ± 45 648 ± 78* 517 ± 61* 
TNF-α (pg/mL) 13 ± 1 8 ± 1 30 ± 9 17 ± 1* 
IL-6 (pg/mL) 108 ± 24 129 ± 35 2130 ± 222* 1685 ± 101* 
IL-1β, interleukin-1β; IL-6, interleukin-6; LPS, lipopolysaccharide; SL, spironolactone TNF-
α, tumor necrosis factor-α. 
*P < 0.05 vs. control; #P < 0.05 vs. LPS. n = 3-4. 
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